{"id":"glibenclamide","rwe":[],"tags":[{"label":"Sulfonylurea","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sulfonylurea receptor 1, Kir6.2","category":"target"},{"label":"ABCC8","category":"gene"},{"label":"KCNJ11","category":"gene"},{"label":"ABCC9","category":"gene"},{"label":"A10BB01","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Active","category":"status"},{"label":"Diabetes mellitus type 2","category":"indication"},{"label":"Neonatal diabetes mellitus","category":"indication"},{"label":"Sanofi Aventis Us","category":"company"},{"label":"Approved 1980s","category":"decade"},{"label":"Hypoglycemic Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":2075.22,"date":"","count":1059,"signal":"Hypoglycaemia","source":"DrugCentral FAERS","actionTaken":"Reported 1,059 times (LLR=2075)"},{"llr":644.806,"date":"","count":563,"signal":"Blood glucose increased","source":"DrugCentral FAERS","actionTaken":"Reported 563 times (LLR=645)"},{"llr":326.089,"date":"","count":478,"signal":"Myocardial infarction","source":"DrugCentral FAERS","actionTaken":"Reported 478 times (LLR=326)"},{"llr":322.579,"date":"","count":206,"signal":"Blood glucose decreased","source":"DrugCentral FAERS","actionTaken":"Reported 206 times (LLR=323)"},{"llr":310.666,"date":"","count":408,"signal":"Cardiac failure congestive","source":"DrugCentral FAERS","actionTaken":"Reported 408 times (LLR=311)"},{"llr":305.238,"date":"","count":280,"signal":"Coronary artery disease","source":"DrugCentral FAERS","actionTaken":"Reported 280 times (LLR=305)"},{"llr":268.586,"date":"","count":255,"signal":"Lactic acidosis","source":"DrugCentral FAERS","actionTaken":"Reported 255 times (LLR=269)"},{"llr":219.22,"date":"","count":142,"signal":"Glycosylated haemoglobin increased","source":"DrugCentral FAERS","actionTaken":"Reported 142 times (LLR=219)"},{"llr":168.157,"date":"","count":210,"signal":"Hyperglycaemia","source":"DrugCentral FAERS","actionTaken":"Reported 210 times (LLR=168)"},{"llr":166.228,"date":"","count":236,"signal":"Off label use","source":"DrugCentral FAERS","actionTaken":"Reported 236 times (LLR=166)"},{"llr":163.503,"date":"","count":128,"signal":"Diabetes mellitus inadequate control","source":"DrugCentral FAERS","actionTaken":"Reported 128 times (LLR=164)"},{"llr":107.122,"date":"","count":3,"signal":"Systemic lupus erythematosus","source":"DrugCentral FAERS","actionTaken":"Reported 3 times (LLR=107)"},{"llr":104.973,"date":"","count":52,"signal":"Hypoglycaemic coma","source":"DrugCentral FAERS","actionTaken":"Reported 52 times (LLR=105)"},{"llr":100.056,"date":"","count":439,"signal":"Drug ineffective","source":"DrugCentral FAERS","actionTaken":"Reported 439 times (LLR=100)"},{"llr":96.793,"date":"","count":203,"signal":"Hyperkalaemia","source":"DrugCentral FAERS","actionTaken":"Reported 203 times (LLR=97)"}],"drugInteractions":[{"url":"/drug/labetalol","drug":"labetalol","action":"Monitor closely","effect":"May interact with Glyburide, Labetalol","source":"DrugCentral","drugSlug":"labetalol"},{"url":"/drug/levofloxacin","drug":"levofloxacin","action":"Monitor closely","effect":"May interact with Glyburide, Levofloxacin","source":"DrugCentral","drugSlug":"levofloxacin"},{"url":"/drug/metoprolol","drug":"metoprolol","action":"Monitor closely","effect":"May interact with Glyburide, Metoprolol","source":"DrugCentral","drugSlug":"metoprolol"},{"url":"/drug/nadolol","drug":"nadolol","action":"Monitor closely","effect":"May interact with Glyburide, Nadolol","source":"DrugCentral","drugSlug":"nadolol"},{"url":"/drug/norfloxacin","drug":"norfloxacin","action":"Monitor closely","effect":"May interact with Glyburide, Norfloxacin","source":"DrugCentral","drugSlug":"norfloxacin"},{"url":"/drug/ofloxacin","drug":"ofloxacin","action":"Monitor closely","effect":"May interact with Glyburide, Ofloxacin","source":"DrugCentral","drugSlug":"ofloxacin"},{"url":"/drug/penbutolol","drug":"penbutolol","action":"Monitor closely","effect":"May interact with Glyburide, Penbutolol","source":"DrugCentral","drugSlug":"penbutolol"},{"url":"/drug/pindolol","drug":"pindolol","action":"Monitor closely","effect":"May interact with Glyburide, Pindolol","source":"DrugCentral","drugSlug":"pindolol"},{"url":"/drug/propranolol","drug":"propranolol","action":"Monitor closely","effect":"May interact with Glyburide, Propranolol","source":"DrugCentral","drugSlug":"propranolol"},{"url":"/drug/rifampicin","drug":"rifampicin","action":"Monitor closely","effect":"May interact with Glyburide, Rifampin","source":"DrugCentral","drugSlug":"rifampicin"},{"url":"/drug/sotalol","drug":"sotalol","action":"Monitor closely","effect":"May interact with Glyburide, Sotalol","source":"DrugCentral","drugSlug":"sotalol"},{"url":"/drug/sulfamethoxazole","drug":"sulfamethoxazole","action":"Monitor closely","effect":"May interact with Glyburide, Sulfamethoxazole","source":"DrugCentral","drugSlug":"sulfamethoxazole"},{"url":"/drug/timolol","drug":"timolol","action":"Monitor closely","effect":"May interact with Glyburide, Timolol","source":"DrugCentral","drugSlug":"timolol"},{"url":"/drug/voriconazole","drug":"voriconazole","action":"Monitor closely","effect":"May interact with Glyburide, Voriconazole","source":"DrugCentral","drugSlug":"voriconazole"}],"commonSideEffects":[],"contraindications":["Acute nephropathy","Acute vomiting","Adrenal cortical hypofunction","Alcohol intoxication","Alcoholism","Asthenia","Cardiogenic shock","Cobalamin deficiency","Decompensated cardiac failure","Dehydration","Disease of liver","Fever","Fever greater than 100.4 Fahrenheit","Glucose-6-phosphate dehydrogenase deficiency anemia","Hemolytic anemia","Hepatic failure","Hepatic porphyria","Hypoglycemic disorder","Hypopituitarism","Infectious disease","Ketoacidosis","Kidney disease","Lactic acidosis","Metabolic acidosis","Myocardial infarction"],"specialPopulations":{"Pregnancy":"Glyburide tablets are not recommended for use in pregnancy. Use during pregnancy only if clearly needed. No adequate and well controlled studies in pregnant women.","Geriatric use":"Elderly patients are particularly susceptible to the hypoglycemic action of glucose lowering drugs. The initial and maintenance dosing should be conservative to avoid hypoglycemic reactions. Dose selection should include assessment of renal function.","Paediatric use":"Safety and effectiveness in pediatric patients have not been established.","Renal impairment":"The initial and maintenance dosing should be conservative to avoid hypoglycemic reactions. Dose selection should include assessment of renal function.","Hepatic impairment":"The initial and maintenance dosing should be conservative to avoid hypoglycemic reactions."}},"trials":[],"aliases":["Glibenclamida, Legrand GE","Daonil","GlibenTek","Sulfonylureas","encephaledema"],"company":"Sanofi","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=glibenclamide","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:17:06.370242+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:17:12.174996+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:17:06.442021+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=glibenclamide","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:17:12.512482+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Sulfonylurea receptor 1, Kir6.2 blocker","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:17:13.570495+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL472/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:17:13.221784+00:00"}},"allNames":"micronase","offLabel":[],"synonyms":["glyburide","glibenclamide","glicuformine"],"timeline":[{"date":"1984-05-01","type":"positive","source":"DrugCentral","milestone":"FDA approval (Sanofi Aventis Us)"},{"date":"2018-05-24","type":"positive","source":"DrugCentral","milestone":"EMA approval (Ammtek)"}],"approvals":[{"date":"1984-05-01","orphan":false,"company":"SANOFI AVENTIS US","regulator":"FDA"},{"date":"2018-05-24","orphan":true,"company":"Ammtek","regulator":"EMA"}],"brandName":"Micronase","ecosystem":[{"indication":"Diabetes mellitus type 2","otherDrugs":[{"name":"acarbose","slug":"acarbose","company":"Bayer Hlthcare"},{"name":"acetohexamide","slug":"acetohexamide","company":"Lilly"},{"name":"albiglutide","slug":"albiglutide","company":"Glaxosmithkline Llc"},{"name":"alogliptin","slug":"alogliptin","company":"Takeda Pharms Usa"}],"globalPrevalence":537000000},{"indication":"Neonatal diabetes mellitus","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Sulfonylurea receptor 1, Kir6.2","novelty":"Follow-on","targets":[{"gene":"ABCC8","source":"DrugCentral","target":"Sulfonylurea receptor 1, Kir6.2","protein":"ATP-binding cassette sub-family C member 8"},{"gene":"KCNJ11","source":"DrugCentral","target":"Sulfonylurea receptor 1, Kir6.2","protein":"ATP-sensitive inward rectifier potassium channel 11"},{"gene":"ABCC9","source":"DrugCentral","target":"Sulfonylurea receptor 2, Kir6.2","protein":"ATP-binding cassette sub-family C member 9"},{"gene":"PPARG","source":"DrugCentral","target":"Peroxisome proliferator-activated receptor gamma","protein":"Peroxisome proliferator-activated receptor gamma"},{"gene":"CYP2C9","source":"DrugCentral","target":"Cytochrome P450 2C9","protein":"Cytochrome P450 2C9"},{"gene":"CISD1","source":"DrugCentral","target":"CDGSH iron-sulfur domain-containing protein 1","protein":"CDGSH iron-sulfur domain-containing protein 1"},{"gene":"ABCB11","source":"DrugCentral","target":"Bile salt export pump","protein":"Bile salt export pump"},{"gene":"NLRP3","source":"DrugCentral","target":"NACHT, LRR and PYD domains-containing protein 3","protein":"NACHT, LRR and PYD domains-containing protein 3"},{"gene":"CFTR","source":"DrugCentral","target":"Cystic fibrosis transmembrane conductance regulator","protein":"Cystic fibrosis transmembrane conductance regulator"},{"gene":"KCNH2","source":"DrugCentral","target":"Potassium voltage-gated channel subfamily H member 2","protein":"Potassium voltage-gated channel subfamily H member 2"}],"modality":"Small Molecule","drugClass":"Sulfonylurea","explanation":"","oneSentence":"","technicalDetail":"Micronase binds to the sulfonylurea receptor 1 (SUR1) and Kir6.2 subunit of the ATP-sensitive potassium channel, inhibiting the channel's activity and leading to membrane depolarization, calcium influx, and subsequent insulin release from pancreatic beta cells."},"commercial":{"launchDate":"1984","_launchSource":"DrugCentral (FDA 1984-05-01, SANOFI AVENTIS US)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1314","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=glibenclamide","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=glibenclamide","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T11:45:23.271168","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:17:15.060815+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"chlorpropamide","drugSlug":"chlorpropamide","fdaApproval":"1958-10-28","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tolbutamide","drugSlug":"tolbutamide","fdaApproval":"1961-06-22","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tolazamide","drugSlug":"tolazamide","fdaApproval":"1966-07-18","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"glipizide","drugSlug":"glipizide","fdaApproval":"1984-05-08","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"glimepiride","drugSlug":"glimepiride","fdaApproval":"1995-11-30","genericCount":17,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"acetohexamide","drugSlug":"acetohexamide","fdaApproval":"1964-12-23","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"glibenclamide","indications":{"approved":[{"name":"Diabetes mellitus type 2","source":"DrugCentral","snomedId":44054006,"regulator":"FDA","eligibility":"adults","usPrevalence":37300000,"globalPrevalence":537000000,"prevalenceMethod":"curated","prevalenceSource":"IDF Diabetes Atlas, 2024"},{"name":"Neonatal diabetes mellitus","source":"DrugCentral","snomedId":49817004,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"chlorpropamide","brandName":"chlorpropamide","genericName":"chlorpropamide","approvalYear":"1958","relationship":"same-class"},{"drugId":"tolbutamide","brandName":"tolbutamide","genericName":"tolbutamide","approvalYear":"1961","relationship":"same-class"},{"drugId":"tolazamide","brandName":"tolazamide","genericName":"tolazamide","approvalYear":"1966","relationship":"same-class"},{"drugId":"glipizide","brandName":"glipizide","genericName":"glipizide","approvalYear":"1984","relationship":"same-class"},{"drugId":"glimepiride","brandName":"glimepiride","genericName":"glimepiride","approvalYear":"1995","relationship":"same-class"},{"drugId":"acetohexamide","brandName":"acetohexamide","genericName":"acetohexamide","approvalYear":"1964","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06907472","phase":"NA","title":"Diabetes Management for Primary Healthcare Centers.","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Abuja","startDate":"2025-09-15","conditions":["Type 2 Diabetes Mellitus (T2DM)"],"enrollment":106,"completionDate":"2026-12-14"},{"nctId":"NCT05426681","phase":"PHASE1","title":"Spinal Cord Injury Neuroprotection With Glyburide","status":"RECRUITING","sponsor":"Francis Farhadi","startDate":"2022-07-07","conditions":["Acute Spinal Cord Injury"],"enrollment":12,"completionDate":"2028-05"},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":["Cardiovascular Events","Type2 Diabetes","Renal Disease"],"enrollment":781430,"completionDate":"2026-07-01"},{"nctId":"NCT00610038","phase":"PHASE2","title":"Efficacy and Safety Study of Sulfonylureas in Neonatal Diabetes Mellitus","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2006-07","conditions":["Diabetes Mellitus"],"enrollment":19,"completionDate":"2011-12"},{"nctId":"NCT05687500","phase":"PHASE2","title":"Oral Glibenclamide in Preterm Infants With Hyperglycaemia (GALOP)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-05-20","conditions":["Transient; Hypoglycemia, Neonatal","Preterm","Glibenclamide Adverse Reaction"],"enrollment":35,"completionDate":"2027-02-20"},{"nctId":"NCT07221799","phase":"PHASE1","title":"OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2026-09-01","conditions":["Multiple Sclerosis","Neuropathic Pain"],"enrollment":10,"completionDate":"2029-09-01"},{"nctId":"NCT02375828","phase":"PHASE3","title":"Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP Channels","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-03-20","conditions":["Neonatal Diabetes Secondary to Mutation in the Potassium Channel"],"enrollment":10,"completionDate":"2019-07-22"},{"nctId":"NCT01731431","phase":"PHASE3","title":"Multicenter Randomized Trial of Non-inferiority Between Glyburide and Insulin for the Treatment of Gestational Diabetes","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-05-18","conditions":["Diabetes","Gestational"],"enrollment":914,"completionDate":"2017-06-02"},{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":["Diabetes Mellitus, Type 2","Cardiovascular Diseases"],"enrollment":714582,"completionDate":"2018-06-25"},{"nctId":"NCT01242215","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-09-17","conditions":["Type 2 Diabetes Mellitus"],"enrollment":243,"completionDate":"2012-04-25"},{"nctId":"NCT05910554","phase":"PHASE2","title":"Investigation of the Efficacy of Metformin Therapy on Pulmonary Sarcoidosis","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2025-12-10","conditions":["Sarcoidosis, Pulmonary"],"enrollment":0,"completionDate":"2027-09-01"},{"nctId":"NCT03029702","phase":"PHASE4","title":"Metabolic Analysis for Treatment Choice in Gestational Diabetes Mellitus","status":"COMPLETED","sponsor":"Maisa N. Feghali, MD","startDate":"2018-02-28","conditions":["Gestational Diabetes","Diabetes, Gestational","Pregnancy in Diabetes"],"enrollment":54,"completionDate":"2023-08-31"},{"nctId":"NCT03954041","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of BIIB093 in Participants With Brain Contusion","status":"TERMINATED","sponsor":"Remedy Pharmaceuticals, Inc.","startDate":"2019-10-06","conditions":["Brain Contusion"],"enrollment":92,"completionDate":"2023-06-27"},{"nctId":"NCT02864953","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction","status":"TERMINATED","sponsor":"Remedy Pharmaceuticals, Inc.","startDate":"2018-08-29","conditions":["Brain Edema","Stroke, Acute"],"enrollment":535,"completionDate":"2023-08-18"},{"nctId":"NCT01268683","phase":"PHASE1,PHASE2","title":"Glyburide Advantage in Malignant Edema and Stroke Pilot","status":"COMPLETED","sponsor":"Remedy Pharmaceuticals, Inc.","startDate":"2011-05-26","conditions":["Ischemic Stroke"],"enrollment":10,"completionDate":"2012-06-07"},{"nctId":"NCT00965991","phase":"NA","title":"Metformin Compared to Glyburide in Gestational Diabetes","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2003-07","conditions":["Gestational Diabetes"],"enrollment":149,"completionDate":"2023-08"},{"nctId":"NCT01794182","phase":"PHASE2","title":"Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals","status":"COMPLETED","sponsor":"Remedy Pharmaceuticals, Inc.","startDate":"2013-06-13","conditions":["Ischemic Stroke","Malignant Edema"],"enrollment":86,"completionDate":"2016-04-04"},{"nctId":"NCT01454154","phase":"PHASE2","title":"Glyburide (RP-1127) for Traumatic Brain Injury (TBI)","status":"COMPLETED","sponsor":"Remedy Pharmaceuticals, Inc.","startDate":"2011-12-17","conditions":["Traumatic Brain Injury"],"enrollment":29,"completionDate":"2015-02-20"},{"nctId":"NCT06589141","phase":"NA","title":"Comparison Between Metformin and Glyburide in the Management of Gestational Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-01-01","conditions":["Gestational Diabetes Mellitus in Pregnancy"],"enrollment":180,"completionDate":"2026-06-30"},{"nctId":"NCT01107717","phase":"PHASE4","title":"Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2009-01","conditions":["Diabetes"],"enrollment":318,"completionDate":"2023-02-03"},{"nctId":"NCT06570980","phase":"","title":"Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.","status":"RECRUITING","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-08-25","conditions":["Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin"],"enrollment":200,"completionDate":"2024-08-30"},{"nctId":"NCT00835991","phase":"PHASE1","title":"Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fed","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2003-02","conditions":["Healthy"],"enrollment":60,"completionDate":"2003-02"},{"nctId":"NCT00836472","phase":"PHASE1","title":"Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fasting","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2003-04","conditions":["Healthy"],"enrollment":60,"completionDate":"2003-04"},{"nctId":"NCT05751525","phase":"","title":"Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome","status":"RECRUITING","sponsor":"Royal Devon and Exeter NHS Foundation Trust","startDate":"2016-07-01","conditions":["Neurodevelopmental Disorders","Intellectual Disability","Development Delay","ADHD","Autism Spectrum Disorder","Epilepsy"],"enrollment":21,"completionDate":"2025-12-31"},{"nctId":"NCT00267683","phase":"PHASE3","title":"Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2005-12","conditions":["Diabetes","Diabetes Mellitus, Type 2"],"enrollment":9,"completionDate":"2006-04"},{"nctId":"NCT05688332","phase":"PHASE3","title":"Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM Patients","status":"UNKNOWN","sponsor":"University of Zambia","startDate":"2023-08","conditions":["Diabetes Mellitus Type 2 Without Complication"],"enrollment":118,"completionDate":"2024-01"},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":["Diabetes Mellitus, Type 2"],"enrollment":550000,"completionDate":"2024-06-30"},{"nctId":"NCT03284463","phase":"PHASE2,PHASE3","title":"Safety and Efficacy of Glibenclamide Combined With Rt-PA in Acute Cerebral Embolism","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-01-01","conditions":["Acute Stroke"],"enrollment":306,"completionDate":"2023-05-28"},{"nctId":"NCT02919345","phase":"PHASE4","title":"Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2017-01","conditions":["Diabetes Mellitus, Type 2","Coronary Artery Disease","Carotid Artery Diseases"],"enrollment":98,"completionDate":"2019-03"},{"nctId":"NCT01131182","phase":"PHASE4","title":"Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-13","conditions":["Type 2 Diabetes Mellitus (T2DM)"],"enrollment":1147,"completionDate":"2010-11-04"},{"nctId":"NCT02460874","phase":"PHASE1,PHASE2","title":"Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases (RAD 1502/UAB 1593)","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2017-08-16","conditions":["Cerebral Edema","Brain Metastases"],"enrollment":1,"completionDate":"2021-05-19"},{"nctId":"NCT03886922","phase":"NA","title":"The Hemodynamics Effect of Glibenclamide on Levcromakalim Assessed by High Resolution Magnetic Resonance Angiography (MRA) Technique in a Randomized Double-blind Cross-over Placebo-controlled Study With Healthy Volunteers","status":"UNKNOWN","sponsor":"Danish Headache Center","startDate":"2019-04-01","conditions":["Hemodynamics of Cranial Arteries","Headache","Cerebral Blood Flow"],"enrollment":15,"completionDate":"2023-08-30"},{"nctId":"NCT02524379","phase":"PHASE1,PHASE2","title":"Spinal Cord Injury Neuroprotection With Glyburide","status":"TERMINATED","sponsor":"Ohio State University","startDate":"2017-02-14","conditions":["Acute Spinal Cord Injury"],"enrollment":3,"completionDate":"2021-02-08"},{"nctId":"NCT03741530","phase":"NA","title":"Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage","status":"COMPLETED","sponsor":"Xijing Hospital","startDate":"2018-12-15","conditions":["Intracerebral Hemorrhage"],"enrollment":220,"completionDate":"2020-09-23"},{"nctId":"NCT05137678","phase":"PHASE4","title":"Evaluate the Use of Glibenclamide on Acute aSAH","status":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","startDate":"2021-10-19","conditions":["Subarachnoid Hemorrhage"],"enrollment":110,"completionDate":"2022-12-01"},{"nctId":"NCT05148403","phase":"PHASE1,PHASE2","title":"To Evaluate the Effect of Glibenclamide in Reducing Brain Edema of TBI","status":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","startDate":"2021-10-22","conditions":["Traumatic Brain Injury"],"enrollment":76,"completionDate":"2022-10-01"},{"nctId":"NCT04859452","phase":"PHASE1","title":"A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-05-26","conditions":["Healthy Subjects"],"enrollment":56,"completionDate":"2021-07-09"},{"nctId":"NCT04960657","phase":"NA","title":"The Hemodynamic Effects of PACAP38 After Glibenclamide Administration in Healthy Volunteers","status":"COMPLETED","sponsor":"Danish Headache Center","startDate":"2020-10-20","conditions":["Migraine","Headache","Pain"],"enrollment":22,"completionDate":"2021-03-19"},{"nctId":"NCT01132703","phase":"PHASE1","title":"Safety Study of RP-1127 (Glyburide for Injection) in Healthy Volunteers","status":"COMPLETED","sponsor":"Biogen","startDate":"2010-01-07","conditions":["Traumatic Brain Injury","Stroke"],"enrollment":34,"completionDate":"2010-05-07"},{"nctId":"NCT02297126","phase":"NA","title":"A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-03","conditions":["Adverse Drug Reaction"],"enrollment":4465,"completionDate":"2019-05-03"},{"nctId":"NCT02726490","phase":"EARLY_PHASE1","title":"Glyburide vs Glucovance in the Treatment of GDM","status":"TERMINATED","sponsor":"Texas Tech University Health Sciences Center, El Paso","startDate":"2016-07","conditions":["Gestational Diabetes"],"enrollment":7,"completionDate":"2018-08-14"},{"nctId":"NCT04231617","phase":"NA","title":"The Hemodynamic Effects of CGRP After Glibenclamide Administration in Healthy Volunteers","status":"COMPLETED","sponsor":"Danish Headache Center","startDate":"2020-01-20","conditions":["Hemodynamics of Cranial Arteries","Headache","Cerebral Blood Flow"],"enrollment":20,"completionDate":"2020-09-01"},{"nctId":"NCT00744965","phase":"PHASE4","title":"Treatment of Mild Gestational Diabetes With Glyburide Versus Placebo","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2008-09-16","conditions":["Mild Gestational Diabetes"],"enrollment":395,"completionDate":"2016-01"},{"nctId":"NCT02624830","phase":"PHASE4","title":"Long-Term Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR)","status":"UNKNOWN","sponsor":"Haukeland University Hospital","startDate":"2019-02-15","conditions":["Permanent Neonatal Diabetes Mellitus"],"enrollment":30,"completionDate":"2020-02"},{"nctId":"NCT04239586","phase":"PHASE4","title":"Switching From Insulin to Sulfonylurea in Diabetes Associated With Variants in MODY Genes","status":"UNKNOWN","sponsor":"Haukeland University Hospital","startDate":"2017-04-18","conditions":["Maturity-Onset Diabetes of the Young, Type 3","Maturity Onset Diabetes of the Young, Type 1","Childhood Diabetes Mellitus","Insulin-dependent Diabetes Mellitus"],"enrollment":30,"completionDate":"2022-04"},{"nctId":"NCT03856970","phase":"PHASE1","title":"Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Ironwood Pharmaceuticals, Inc.","startDate":"2019-03-11","conditions":["Healthy Volunteers"],"enrollment":87,"completionDate":"2019-07-03"},{"nctId":"NCT03855306","phase":"PHASE1","title":"A Bioequivalence Study of Glibenclamide From Glibesyn 5 mg Tablets (Medochemie LTD Cyprus) and Daonil 5 mg Tablets (Sanofi-Aventis Cyprus Ltd. )","status":"COMPLETED","sponsor":"Genuine Research Center, Egypt","startDate":"2018-06-30","conditions":["Healthy"],"enrollment":27,"completionDate":"2018-08-15"},{"nctId":"NCT01697592","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":["Type 2 Diabetes Mellitus"],"enrollment":585,"completionDate":"2014-05-08"},{"nctId":"NCT02318693","phase":"PHASE4","title":"Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-02-04","conditions":["Type 2 Diabetes Mellitus"],"enrollment":53,"completionDate":"2015-12-15"},{"nctId":"NCT03569540","phase":"PHASE4","title":"Glibenclamide in Aneurysmatic Subarachnoid Hemorrhage","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2018-07-03","conditions":["Subarachnoid Hemorrhage, Aneurysmal"],"enrollment":50,"completionDate":"2019-12-01"},{"nctId":"NCT03089333","phase":"PHASE4","title":"Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2016-07","conditions":["Hypertension","Diabetes Mellitus, Type 2","Blood Pressure","Obesity","Cardiac Hypertrophy","Microalbuminuria","Vascular Stiffness"],"enrollment":16,"completionDate":"2017-12"},{"nctId":"NCT03078725","phase":"PHASE4","title":"Failure Rate of GLyburide And Metformin Among Gestational Diabetics","status":"WITHDRAWN","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2017-06-20","conditions":["Gestational Diabetes Mellitus, Class A2"],"enrollment":0,"completionDate":"2018-05-10"},{"nctId":"NCT01215331","phase":"PHASE3","title":"Gestational Diabetes: Insulin or Oral Hypoglycemic Agents?","status":"COMPLETED","sponsor":"Université de Sherbrooke","startDate":"2010-08","conditions":["Gestational Diabetes Mellitus"],"enrollment":73,"completionDate":"2016-05"},{"nctId":"NCT00194896","phase":"NA","title":"Preferred Treatment of Type 1.5 Diabetes","status":"COMPLETED","sponsor":"University of Washington","startDate":"2000-02","conditions":["Type 2 Diabetes Mellitus"],"enrollment":64,"completionDate":"2008-12"},{"nctId":"NCT02627898","phase":"PHASE2","title":"Effect of Green Tea Extract on Arterial Stiffness in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Centro Universitario de Ciencias de la Salud, Mexico","startDate":"2016-01","conditions":["Type 2 Diabetes Mellitus"],"enrollment":24,"completionDate":"2016-12"},{"nctId":"NCT00451620","phase":"PHASE2","title":"Effect of GlucoNorm vs Glyburide on Post-Prandial Hyperglycemia in Elderly Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2003-11","conditions":["Type 2 Diabetes"],"enrollment":30,"completionDate":"2011-09"},{"nctId":"NCT00232583","phase":"NA","title":"Preservation of Beta-cell Function in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2003-11","conditions":["Type 2 Diabetes Mellitus"],"enrollment":58,"completionDate":"2011-12"},{"nctId":"NCT00279045","phase":"PHASE3","title":"Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-01-03","conditions":["Diabetes Mellitus, Type 2"],"enrollment":4426,"completionDate":"2006-06-19"},{"nctId":"NCT00333723","phase":"PHASE4","title":"AVANDIA With Glyburide In African American And Hispanic Patients With Type 2 Diabetes Not Controlled by Glyburide Alone","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-07-28","conditions":["Diabetes Mellitus, Type 2"],"enrollment":245,"completionDate":"2003-01-06"},{"nctId":"NCT02624817","phase":"PHASE4","title":"Long-Term Sulfonylurea Response in KCNJ11 Neonatal Diabetes","status":"COMPLETED","sponsor":"Haukeland University Hospital","startDate":"2015-12","conditions":["Permanent Neonatal Diabetes Mellitus"],"enrollment":90,"completionDate":"2016-08"},{"nctId":"NCT01822548","phase":"PHASE3","title":"Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria di Parma","startDate":"2010-10","conditions":["Type 2 Diabetes"],"enrollment":64,"completionDate":"2015-01"},{"nctId":"NCT01340768","phase":"PHASE3","title":"Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-22","conditions":["Type 2 Diabetes Mellitus"],"enrollment":870,"completionDate":"2011-09-21"},{"nctId":"NCT01357135","phase":"","title":"An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-07-15","conditions":["Type 2 Diabetes Mellitus"],"enrollment":3453,"completionDate":"2013-08-31"},{"nctId":"NCT02830048","phase":"PHASE2","title":"Low dosE GlibENclamide in Diabetes Part A","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2016-07","conditions":["Diabetes Mellitus, Type 2"],"enrollment":16,"completionDate":"2017-03-09"},{"nctId":"NCT01798706","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":["Type 2 Diabetes"],"enrollment":350,"completionDate":"2015-02"},{"nctId":"NCT00379769","phase":"PHASE3","title":"RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-04","conditions":["Diabetes Mellitus, Type 2"],"enrollment":4447,"completionDate":"2008-12"},{"nctId":"NCT00393718","phase":"PHASE3","title":"Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-11","conditions":["Diabetes","Diabetes Mellitus, Type 2"],"enrollment":400,"completionDate":"2008-05"},{"nctId":"NCT01698931","phase":"PHASE4","title":"Efficacy of Repaglinide in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-04-26","conditions":["Diabetes","Diabetes Mellitus, Type 2"],"enrollment":9,"completionDate":"2003-03-06"},{"nctId":"NCT01605773","phase":"PHASE4","title":"Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-11-08","conditions":["Diabetes","Diabetes Mellitus, Type 2"],"enrollment":51,"completionDate":"2003-03-13"},{"nctId":"NCT01934816","phase":"NA","title":"Incretin and KATP Channels","status":"TERMINATED","sponsor":"Katarina Kos","startDate":"2013-06","conditions":["Healthy Subjects"],"enrollment":2,"completionDate":"2015-10"},{"nctId":"NCT02080377","phase":"PHASE3","title":"A Feasibility Study Looking at the Use of Glibenclamide and metfoRmin Versus stAndard Care in gEstational diabeteS","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2014-07","conditions":["Pregnancy","Gestational Diabetes"],"enrollment":23,"completionDate":"2016-03"},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":["Diabetes Mellitus, Type 2"],"enrollment":1417914,"completionDate":"2015-04"},{"nctId":"NCT00388986","phase":"PHASE1","title":"A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-10","conditions":["Diabetes Mellitus Type 2"],"enrollment":18,"completionDate":"2007-07"},{"nctId":"NCT01563120","phase":"PHASE4","title":"A Comparison Between Two Oral Hypoglycemics - Metformin and Glybenclamide for the Treatment of Gestational Diabetes Mellitus","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2012-01","conditions":["Gestational Diabetes Mellitus"],"enrollment":108,"completionDate":"2014-12"},{"nctId":"NCT00734669","phase":"","title":"Risk of Hypoglycemia in Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Giessen","startDate":"2008-07","conditions":["Type 2 Diabetes"],"enrollment":12,"completionDate":"2016-10"},{"nctId":"NCT01944618","phase":"","title":"forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2013-10","conditions":["Type 2 Diabetes"],"enrollment":5000,"completionDate":"2015-10"},{"nctId":"NCT02201602","phase":"PHASE4","title":"Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study","status":"COMPLETED","sponsor":"Khoo Teck Puat Hospital","startDate":"2014-08","conditions":["Diabetes"],"enrollment":8,"completionDate":"2016-07"},{"nctId":"NCT02145611","phase":"PHASE4","title":"Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension","status":"COMPLETED","sponsor":"Dr. José Fernando Vilela-Martin MD PhD","startDate":"2013-07","conditions":["Type 2 Diabetes Mellitus","Hypertension","Endothelial Dysfunction"],"enrollment":50,"completionDate":"2016-05"},{"nctId":"NCT02815787","phase":"PHASE1","title":"The Drug -Drug Interaction of SP2086 and Glyburide","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2014-03","conditions":["Type 2 Diabetes"],"enrollment":16,"completionDate":"2014-07"},{"nctId":"NCT01947699","phase":"PHASE4","title":"Glycemic Profile in Women With Gestational Diabetes Treated With Glyburide","status":"WITHDRAWN","sponsor":"University of Pittsburgh","startDate":"2013-09","conditions":["Gestational Diabetes"],"enrollment":0,"completionDate":"2014-09"},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":["Type 2 Diabetes Mellitus"],"enrollment":1499650,"completionDate":"2015-05"},{"nctId":"NCT02128022","phase":"PHASE1","title":"Cardioprotective Effects of GLP-1 and Their Mechanisms","status":"COMPLETED","sponsor":"Papworth Hospital NHS Foundation Trust","startDate":"2014-07","conditions":["Angina Pectoris"],"enrollment":32,"completionDate":"2016-03"},{"nctId":"NCT02475499","phase":"","title":"Incretin-based Drugs and Pancreatic Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":["Diabetes Mellitus, Type 2"],"enrollment":886172,"completionDate":"2015-04"},{"nctId":"NCT01540396","phase":"NA","title":"Gestational Diabetes Diagnostic Methods","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2012-02","conditions":["Gestational Diabetes"],"enrollment":47,"completionDate":"2014-12"},{"nctId":"NCT00486187","phase":"NA","title":"Effects of ROSIglitazone on Inflammatory Markers and Adipokines in Diabetic Patients Using an Angiotensin Receptor Blocker (TELmisartan) - The ROSITEL Study","status":"COMPLETED","sponsor":"Dr. Milan Gupta","startDate":"2006-04","conditions":["Type 2 Diabetes Mellitus"],"enrollment":103,"completionDate":"2009-06"},{"nctId":"NCT02607410","phase":"PHASE4","title":"Sitagliptin (DPP-4 Inhibitor) and NPH Insulin in Patients With T2D","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2010-01","conditions":["Type 2 Diabetes Mellitus"],"enrollment":40,"completionDate":"2014-07"},{"nctId":"NCT00700856","phase":"PHASE4","title":"Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial","status":"UNKNOWN","sponsor":"Italian Society of Diabetology","startDate":"2008-09","conditions":["Type 2 Diabetes Mellitus","Cardiovascular Disease"],"enrollment":3371,"completionDate":"2018-12"},{"nctId":"NCT00313313","phase":"PHASE3","title":"A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-04","conditions":["Diabetes"],"enrollment":768,"completionDate":"2008-09"},{"nctId":"NCT02406950","phase":"PHASE3","title":"Sitagliptin and Endothelial Dysfunction","status":"UNKNOWN","sponsor":"Kyunghee University Medical Center","startDate":"2015-02","conditions":["Healthy"],"enrollment":10,"completionDate":"2015-08"},{"nctId":"NCT01998113","phase":"","title":"Glyburide and Metformin for the Treatment of Gestational Diabetes Mellitus. Systematic Review","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2013-03","conditions":["Gestational Diabetes Mellitus"],"enrollment":2509,"completionDate":"2014-05"},{"nctId":"NCT01329016","phase":"PHASE1,PHASE2","title":"Glyburide and Metformin for Gestational Diabetes Mellitus (GDM)","status":"UNKNOWN","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2011-07","conditions":["Gestational Diabetes Mellitus"],"enrollment":360,"completionDate":"2015-06"},{"nctId":"NCT00935363","phase":"PHASE1","title":"Interplay Between Organic Anion Transporting Polypeptide (OATP) Transporters Transporters and CYP2C9 in Glyburide Pharmacokinetics (PK)","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2010-02","conditions":["Healthy"],"enrollment":0,"completionDate":"2010-04"},{"nctId":"NCT00608179","phase":"NA","title":"Glimepiride Induced Insulin Secretion Will be Inhibited by Hypoglycemia","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2002-08","conditions":["Type 2 Diabetes"],"enrollment":32,"completionDate":"2010-12"},{"nctId":"NCT01584232","phase":"PHASE3","title":"A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-04","conditions":["Type 2 Diabetes Mellitus"],"enrollment":361,"completionDate":"2013-07"},{"nctId":"NCT02255006","phase":"NA","title":"Effect of Acupuncture to Endothelial Dysfunction Induced by Ischemia-reperfusion Injury","status":"UNKNOWN","sponsor":"Kyunghee University Medical Center","startDate":"2014-05","conditions":["Healthy"],"enrollment":36,"completionDate":"2014-12"},{"nctId":"NCT01716338","phase":"PHASE1","title":"Glyburide Healthy Volunteer Study","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2013-01","conditions":["Healthy Volunteers"],"enrollment":21,"completionDate":"2014-08"},{"nctId":"NCT02183428","phase":"PHASE1","title":"Bioavailability of BI 1356 and Glyburide in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-05","conditions":["Healthy"],"enrollment":20,"completionDate":""},{"nctId":"NCT01940302","phase":"EARLY_PHASE1","title":"Dietary Supplement of LEHEL for the Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Shaoguan University","startDate":"2013-06","conditions":["Type 2 Diabetes"],"enrollment":71,"completionDate":"2014-03"},{"nctId":"NCT01867502","phase":"PHASE4","title":"Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2014-04","conditions":["Diabetes Mellitus, Type 2","Hypoglycemic Agents","Diabetic Blood Glucose Monitoring","Exercise"],"enrollment":20,"completionDate":"2015-08"},{"nctId":"NCT02091336","phase":"PHASE4","title":"Oral Antidiabetic Agents in Pregnancy","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2014-01","conditions":["Gestational Diabetes"],"enrollment":80,"completionDate":"2016-12"}],"whoEssential":true,"_emaApprovals":[{"date":"2018-05-24","status":"Authorised","company":"Ammtek"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET","route":"ORAL","productName":"GLYBURIDE"},{"form":"TABLET","route":"ORAL","productName":"GLYBURIDE AND METFORMIN HYDROCHLORIDE"},{"form":"TABLET","route":"ORAL","productName":"Glyburide"},{"form":"TABLET","route":"ORAL","productName":"Glyburide and Metformin Hydrochloride"},{"form":"TABLET","route":"ORAL","productName":"Glyburide-Metformin Hydrochloride"},{"form":"TABLET","route":"ORAL","productName":"glyBURIDE"},{"form":"TABLET","route":"ORAL","productName":"glyburide"},{"form":"TABLET","route":"ORAL","productName":"glyburide and metformin hydrochloride"},{"form":"TABLET","route":"ORAL","productName":"Glynase"},{"form":"TABLET","route":"ORAL","productName":"Glyburide"},{"form":"TABLET","route":"ORAL","productName":"Glyburide"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"GLYBURIDE AND METFORMIN HYDROCHLORIDE"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Glyburide and Metformin"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Glyburide and Metformin Hydrochloride"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"GLUCOVANCE"}]},"crossReferences":{"NUI":"N0000146417","MMSL":"4790","NDDF":"000912","UNII":"SX6K58TVWC","VUID":"4018078","CHEBI":"CHEBI:5441","VANDF":"4018078","INN_ID":"2386","RXNORM":"4815","UMLSCUI":"C0017628","chemblId":"CHEMBL472","ChEMBL_ID":"CHEMBL472","KEGG_DRUG":"D00336","DRUGBANK_ID":"DB01016","PDB_CHEM_ID":" GBM","PUBCHEM_CID":"3488","SNOMEDCT_US":"384978002","IUPHAR_LIGAND_ID":"2414","MESH_DESCRIPTOR_UI":"D005905"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1984-","companyName":"Sanofi","relationship":"Original Developer"},{"period":"2018","companyName":"Ammtek","relationship":"EMA Licensee"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"2.2 hours","clearance":"0.82 mL/min/kg","bioavailability":"82%","fractionUnbound":"0.021%","volumeOfDistribution":"0.08 L/kg"},"publicationCount":9337,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"A10BB01","allCodes":["A10BB01"]},"biosimilarFilings":[],"originalDeveloper":"Sanofi Aventis Us","recentPublications":[],"combinationProducts":[{"brandName":"GLUCOVANCE","ingredients":"glibenclamide + metformin"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"1984","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1984-05-01T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":""},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1984-05-01T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1984-05-01T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1984-05-01T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1984-05-01T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1984-05-01T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:17:15.060815+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}